Interview with Keith Martin, CEO, Apitope
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
Address: Bristol & Bath Science Park
Dirac Crescent
Emersons Green
Bristol
BS16 7FR
United Kingdom
Tel: +44 (0)117 370 7720
Apitope is a privately owned European biotech company developing antigen specific therapeutic peptides for the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves’ disease, Uveitis, and others.
Autoimmune disease arises from our own immune system responding incorrectly to the proteins and complex tissues that make up our body. For example, multiple sclerosis is caused by immune cells attacking the myelin sheath that insulates the neurons within nervous system including the brain and spinal cord.
Our research team is currently developing peptide based therapeutics designed to selectively suppress this aberrant interaction between immune cell and protein antigen, reinstating the body’s natural immune tolerance to the body’s own proteins.
This approach is founded on peer reviewed research demonstrating that treatment with a soluble, synthetic peptide derived from a known antigenic protein (such as myelin basic protein; a constituent of myelin) can prevent the immune system from responding to that protein as a threat.
In order to induce this process of immune-tolerance we must first identify the region within an antigen that the immune system recognises as a threat during an autoimmune disease. This region is referred to as an epitope.
However, Apitope has shown that in order for an epitope to effectively suppress disease it must behave as an Apitope® – Antigen Processing Independent epiTOPE. Our patented discovery platform enables us to efficiently identify and design these unique peptide therapeutics.
We aim to become the partner of choice for companies developing disease modifying therapies for autoimmune diseases and allergies.
Driving us towards this goal, Apitope has an highly experienced senior management team, each with a proven track record in the translation of novel therapeutics from bench to bedside.
Apitope’s most advanced product candidate, ATX-MS-1467, is undergoing Phase I trials in patients with multiple sclerosis. Our clinical development team is working in partnership with Merck-Serono, a leading company in the development and marketing of MS therapies, to move our product ahead as quickly and effectively as possible.
The company’s lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
A roundup of the biggest stories from UK pharma, including the latest agreement between the British government and industry on a renewed drug pricing clawback scheme; GSK’s search for deals…
AstraZeneca has made a bold move by offering its in-house digital clinical trial expertise to clinical research organisations (CROs) and other pharmaceutical companies via the launch of healthtech business Evinova.…
Since its creation over 20 years ago, the National Institute for Health and Care Excellence (NICE), the Health Technology Assessment (HTA) body for England and Wales, has forged a solid…
Could the UK’s re-joining of Horizon Europe, the EU’s EUR 95 billion research funding programme, be the latest sign that the country is ready to win back its global scientific…
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report –…
The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National…
See our Cookie Privacy Policy Here
